Abstract
Chronic obstructive pulmonary disease (COPD) is a debilitating respiratory condition, characterised by progressive, irreversible airflow obstruction. The major risk factor for development of COPD is cigarette smoking, and the disease is predicted to become the 3rd leading cause of death by 2020. Currently, there are no pharmacological interventions that halt the progression of COPD; however one strategy is to reduce the chronic lung inflammation associated with this disease. An increased inflammatory infiltrate comprising macrophages, neutrophils and T-lymphocytes is a major hallmark of COPD. Furthermore, both macrophages and neutrophils have the ability to cause all the pathological changes associated with COPD. Chemokines that are elevated in sputum from COPD patients have the capacity to recruit neutrophils, the macrophage precursor cells, monocytes, and T-lymphocytes. Chemokines are considered predominantly chemotactic cytokines however; there is a growing body of evidence demonstrating that chemokines can also act as functional antagonists thus leading to selective recruitment of inflammatory cells. Whilst inhibition of chemokine dependent recruitment of inflammatory cells via small molecule antagonists gives rise to potential treatments for COPD, the discovery that chemokines are also natural antagonists could also be exploited in the ongoing search for treatment of this currently fatal disease.
Keywords: copd, chemokines, receptors, therapeutics, cxcr2, cxcr3
Current Respiratory Medicine Reviews
Title: Chemokines and their Receptors as Targets for the Treatment of COPD
Volume: 1 Issue: 1
Author(s): Suzanne L. Traves and Louise E. Donnelly
Affiliation:
Keywords: copd, chemokines, receptors, therapeutics, cxcr2, cxcr3
Abstract: Chronic obstructive pulmonary disease (COPD) is a debilitating respiratory condition, characterised by progressive, irreversible airflow obstruction. The major risk factor for development of COPD is cigarette smoking, and the disease is predicted to become the 3rd leading cause of death by 2020. Currently, there are no pharmacological interventions that halt the progression of COPD; however one strategy is to reduce the chronic lung inflammation associated with this disease. An increased inflammatory infiltrate comprising macrophages, neutrophils and T-lymphocytes is a major hallmark of COPD. Furthermore, both macrophages and neutrophils have the ability to cause all the pathological changes associated with COPD. Chemokines that are elevated in sputum from COPD patients have the capacity to recruit neutrophils, the macrophage precursor cells, monocytes, and T-lymphocytes. Chemokines are considered predominantly chemotactic cytokines however; there is a growing body of evidence demonstrating that chemokines can also act as functional antagonists thus leading to selective recruitment of inflammatory cells. Whilst inhibition of chemokine dependent recruitment of inflammatory cells via small molecule antagonists gives rise to potential treatments for COPD, the discovery that chemokines are also natural antagonists could also be exploited in the ongoing search for treatment of this currently fatal disease.
Export Options
About this article
Cite this article as:
Traves L. Suzanne and Donnelly E. Louise, Chemokines and their Receptors as Targets for the Treatment of COPD, Current Respiratory Medicine Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573398052953622
DOI https://dx.doi.org/10.2174/1573398052953622 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hematologic Abnormalities in the Antiphospholipid Syndrome
Current Rheumatology Reviews Current Experimental Therapy for Alzheimers Disease
Current Neuropharmacology Retroviral Gene Therapy: Safety Issues and Possible Solutions
Current Gene Therapy Resolving Inflammation in Heart Failure: Novel Protective Lipid Mediators
Current Drug Targets Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Current Pharmaceutical Design Targets of Anti-glucocorticoid Therapy for Stress-related Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Periodontal Ligament Stem Cell Isolation Protocol: A Systematic Review
Current Stem Cell Research & Therapy Progress of Mesenchymal Stem Cell-Derived Exosomes in Tissue Repair
Current Pharmaceutical Design From Stem Cell Biology to The Treatment of Lung Diseases
Current Stem Cell Research & Therapy Practical Application of Antidiabetic Efficacy of <i>Lycium barbarum</i> Polysaccharide in Patients with Type 2 Diabetes
Medicinal Chemistry Hydrogen Sulfide-Based Therapies: Focus on H2S Releasing NSAIDs
Inflammation & Allergy - Drug Targets (Discontinued) Correlates of Immune Protection from Tuberculosis
Current Molecular Medicine Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders
Current Medicinal Chemistry Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Recent Patents on Inflammation & Allergy Drug Discovery Natural Phenolic Compounds as Cardiovascular Therapeutics: Potential Role of their Antiinflammatory Effects
Current Vascular Pharmacology Formulation of Nanoparticles Against TB - A Review
Recent Patents on Inflammation & Allergy Drug Discovery Vitamin D in Chronic Kidney Disease: New Potential for Intervention
Current Drug Targets Stimulator of Interferon Genes Signaling Pathway and its Role in Anti-tumor Immune Therapy
Current Pharmaceutical Design Preface [Hot topic: New Insights into COX-2 Biology and Inhibition (Executive Editor: Paola Patrignani)]
Current Pharmaceutical Design Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience